J&J Alleges Amgen’s Proposed Biosimilar Infringes on Stelara Patents

Johnson & Johnson (J&J) has sued Amgen for allegedly violating its patent protections for blockbuster Stelara (ustekinumab) — a biologic FDA-approved for treating ulcerative colitis, psoriatic arthritis, plaque psoriasis and Crohn’s disease, among other indications.
Source: Drug Industry Daily